Barna B, Deodhar S D
Cancer Res. 1975 Apr;35(4):920-6.
The evolution of immune responses of C57BL/6 mice to allogeneic tumor Sarcoma 180 and of A/J mice to isogeneic tumor Sarcoma 1 was investigated by colony and cell inhibition (CI) assays. The immune response of lymphocytes from regional popliteal nodes, distant nodes, and spleens was examined at varying times after s.c. implantation of known numbers of in vitro-grown tumor cells in the hind feet. In the allogeneic system, only regional node lymphocytes produced CI activity, amximum response appearing at Day 14 and gradually diminishing therafter with tumor regression. Serum-blocking activity was not observed until Day 21 and increased to significant levels by Day 39 when no lymphocyte CI activity was detectable. In the isogeneic system, CI activity was tumor-dose dependent. Responses to low-dose inocula were confined to regional nodes, whereas with high-dose inocula, initial responses were provided by regional nodes, but by Day 21 the spleen had become the primary source of CI activity. Examination of blocking activity in this system was not possible due to nonspecific serum cytotoxicity. Lymph nodes other than regional showed no CI response at any time in either tumor system. These studies demonstrate the importance of regional nodes in the development of immune responses to both allogeneic and osogeneic tumors.
通过集落和细胞抑制(CI)试验研究了C57BL/6小鼠对同种异体肿瘤肉瘤180以及A/J小鼠对同基因肿瘤肉瘤1的免疫反应演变。在已知数量的体外培养肿瘤细胞经皮下接种于后足后不同时间,检测来自局部腘窝淋巴结、远处淋巴结和脾脏的淋巴细胞的免疫反应。在同种异体系统中,只有局部淋巴结淋巴细胞产生CI活性,最大反应出现在第14天,随后随着肿瘤消退逐渐减弱。直到第21天才观察到血清阻断活性,到第39天增加到显著水平,此时检测不到淋巴细胞CI活性。在同基因系统中,CI活性取决于肿瘤剂量。对低剂量接种物的反应局限于局部淋巴结,而对于高剂量接种物,最初的反应由局部淋巴结提供,但到第21天,脾脏已成为CI活性的主要来源。由于非特异性血清细胞毒性,无法在该系统中检测阻断活性。在任一肿瘤系统中,除局部淋巴结外的其他淋巴结在任何时候都没有CI反应。这些研究证明了局部淋巴结在同种异体和同基因肿瘤免疫反应发展中的重要性。